Upgrade to SI Premium - Free Trial

Sarepta Therapeutics (SRPT): Time For Selling Into Strength Is Over - Baird

July 20, 2017 6:06 AM
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) and raised his price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change Earnings

Next Articles